LONDON, Oct 10 (Reuters) - Britain's Oxford BioMedica
said on Wednesday it was closing a mid-stage clinicaltrial of its cancer vaccine TroVax in U.S. patients withprostate cancer, dealing a further blow to the troubled product.
Shares in the company fell more than 9 percent on the news.
The group had been testing TroVax in men with progressivehormone refractory prostate cancer but it faced an uphillstruggle, given the arrival of new products for the disease andother clinical trials targeting the same indication.
As a result, recruitment into the Phase II study was muchslower than hoped with just 26 patients recruited to date.
TroVax, once viewed as Oxford Bio's most promising product,suffered a setback four years ago when it failed in a study forkidney cancer. Despite that blow the company has pushed on withtests in other cancer types.
TroVax is also being assessed in British studies as atreatment for colorectal and ovarian cancer, as well as formesothelioma, a rare form of cancer usually caused by exposureto asbestos.
"Securing a development or financial partner for TroVax'sfuture late-stage development remains a key strategic priorityfor the company and discussions with interested parties areongoing," Oxford Bio added in a statement.
(Reporting by Ben Hirschler; Editing by Hans-Juergen Peters)
Keywords: OXFORDBIOMEDICA TROVAX/